LOXO-338

FCN-338 (LOXO-338) is an orally active and selective Bcl-2 inhibitor with an IC50 of 4.5 nM for Bcl-2/BAK interaction. FCN-338 potently inhibits tumor growth in follicular lymphoma (FL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) xenograft mice model without significant weight loss. FCN-338 has a broad-spectrum anti-cancer activity, such as FL, CLL/SLL, AML, and ALL[1][2].


Cat. No.: EX-A16950	Purity: >98%

	Chemical structure of LOXO-338

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock	Quantity	Order

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	FCN-338
CAS No.	2248046-39-9
Purity	>98%
Formula	C48H48ClN7O7S
Mol Weight	902.455
Color	Light yellow to yellow
State	Solid
Solubility	soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; 4℃, 2 years; In solvent -20℃, 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Brandhuber B, et al. Preclinical characterization of LOXO-338, a novel, oral and selective BCL2 inhibitor[J]. Cancer Research, 2021, 81(13_Supplement): 1258-1258. [2]. Vogler M, et al. The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy. Signal Transduct Target Ther. 2025 Mar 21;10(1):91.
CoA	CoA of LOXO-338

Smiles:	ClC1=CC=C(C=C1)C(CC(C)(CC2)C)=C2CN3CCN(C4=CC=C(C(NS(=O)(C5=CC(OC6)=C(C([N+]([O-])=O)=C5)N[C@H]6CC7=CC=CC=C7)=O)=O)C(OC8=CN=C9NC=CC9=C8)=C4)CC3


		Search